36
Participants
Start Date
August 16, 2017
Primary Completion Date
June 22, 2018
Study Completion Date
June 3, 2020
Concizumab
0.15 mg/kg (with potential stepwise dose administration to 0.25 mg/kg) administered daily s.c (subcutaneously, under the skin). Treatment duration is 24 weeks in the main phase, and 52 weeks in the extension phase
Turoctocog alfa
Breakthrough bleeding episodes will be treated by the patients at home with turoctocog alfa at the discretion of the study doctor, who will also choose dose levels
Novo Nordisk Investigational Site, Bangkok
Novo Nordisk Investigational Site, Caen
Novo Nordisk Investigational Site, Milan
Novo Nordisk Investigational Site, Edirne
Novo Nordisk Investigational Site, Madrid
Novo Nordisk Investigational Site, Málaga
Novo Nordisk Investigational Site, Brest
Novo Nordisk Investigational Site, Istanbul
Novo Nordisk Investigational Site, Bornova-IZMIR
Novo Nordisk Investigational Site, Nashville
Novo Nordisk Investigational Site, Nantes
Novo Nordisk Investigational Site, Valencia
Novo Nordisk Investigational Site, Indianapolis
Novo Nordisk Investigational Site, Bonn
Novo Nordisk Investigational Site, Homburg
Novo Nordisk Investigational Site, Oklahoma City
Novo Nordisk Investigational Site, Lviv
Novo Nordisk Investigational Site, Salt Lake City
Novo Nordisk Investigational Site, Los Angeles
Novo Nordisk Investigational Site, Rome
Novo Nordisk Investigational Site, Aichi
Novo Nordisk Investigational Site, Nara
Novo Nordisk Investigational Site, Tokyo
Novo Nordisk Investigational Site, Tokyo
Novo Nordisk Investigational Site, Malmo
Novo Nordisk Investigational Site, Solna
Novo Nordisk Investigational Site, Ankara
Novo Nordisk Investigational Site, Belfast
Novo Nordisk Investigational Site, Cambridge
Novo Nordisk Investigational Site, London
Novo Nordisk Investigational Site, London
Lead Sponsor
Novo Nordisk A/S
INDUSTRY